Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in c-KIT Mutated Advanced Acral and Mucosal Melanoma
NCT01395121Phase 2Completed
- Sponsor
- The Institute of Cancer Research
- Start
- Dec 2009
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in acral lentiginous melanoma (ALM), mucosal melanoma (MM), sponsored by The Institute of Cancer Research. Started Dec 2009; status: completed.
02
Drugs
nilotinib
03
Conditions
acral lentiginous melanoma (ALM)mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT01395121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01395121.